Combination of pneumococcal surface protein a (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Oliveira, Maria Leonor S ^a   Miyaji, Eliane N ^a   Ferreira, Daniela M ^a,b   Moreno, Adriana T ^a   Ferreira, Patricia C D ^a   Lima, Fernanda A ^a   Santos, Fernanda L ^a   Sakauchi, Maria Aparecida ^a   Takata, Célia S ^a   Higashi, Hisako G ^a   Raw, Isaías ^a   Kubrusly, Flavia S ^a   Ho, Paulo L ^a  

^a INSTITUTO BUTANTAN   (Brazil)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; LIPOPOLYSACCHARIDE; PERTUSSIS VACCINE; PNEUMOCOCCAL SURFACE PROTEIN A5; PNEUMOCOCCUS VACCINE; STREPTOCOCCUS ANTIGEN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BAGG ALBINO MOUSE; BORDETELLA PERTUSSIS; COLONY FORMING UNIT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSS PROTECTION; DRUG POTENTIATION; FEMALE; LUNG LAVAGE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PNEUMOCOCCAL INFECTION; PROTEIN FUNCTION; PROVOCATION TEST; RESPIRATORY TRACT INFECTION; SURVIVAL RATE; VACCINE PRODUCTION; WHOLE CELL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; CROSS PROTECTION; CROSS REACTIONS; IMMUNIZATION; LUNG; MICE; MICE, INBRED BALB C; NASAL MUCOSA; PERTUSSIS VACCINE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RESPIRATORY TRACT DISEASES; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTOR 4;

ANIMALIA; BORDETELLA PERTUSSIS; MUS; STREPTOCOCCUS PNEUMONIAE;

EID: 77956275571     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010863     Document Type: Article

References (69)

1. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, et al. (2009) Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374: 893-902.
2. de Quadros CA (2009) From global to regional: the importance of pneumococcal disease in Latin America. Vaccine 27 Suppl 3: C29-32.
3. Dagan R (2009) New insights on pneumococcal disease: what we have learned over the past decade. Vaccine 27 Suppl 3: C3-5.
4. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, et al. (2010) Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 201: 32-41.
5. Bettinger JA, Scheifele DW, Kellner JD, Halperin SA, Vaudry W, et al. (2009) The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine.
6. Hsu KK, Shea KM, Stevenson AE, Pelton SI (2009) Changing Serotypes Causing Childhood Invasive Pneumococcal Disease: Massachusetts, 2001-2007. Pediatr Infect Dis J.
7. Techasaensiri C, Messina AF, Katz K, Ahmad N, Huang R, et al. (2009) Epidemiology and Evolution of Invasive Pneumococcal Disease Caused by Multidrug Resistant Serotypes of 19A in the 8 Years After Implementation of Pneumococcal Conjugate Vaccine Immunization in Dallas, Texas. Pediatr Infect Dis J.
8. Franco CM, Andrade AL, Andrade JG, Almeida e Silva S, Oliveira CR, et al. (2010) Survey of nonsusceptible nasopharyngeal Streptococcus pneumoniae isolates in children attending day-care centers in Brazil. Pediatr Infect Dis J 29: 77-79.
9. Shouval DS, Greenberg D, Givon-Lavi N, Porat N, Dagan R (2009) Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines. Pediatr Infect Dis J 28: 277-282.
10. Chiba N, Morozumi M, Sunaoshi K, Takahashi S, Takano M, et al. (2010) Serotype and antibiotic resistance of isolates from patients with invasive pneumococcal disease in Japan. Epidemiol Infect 138: 61-68.
11. Tai SS (2006) Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit Rev Microbiol 32: 139-153.
12. Tu AH, Fulgham RL, McCrory MA, Briles DE, Szalai AJ (1999) Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun 67: 4720-4724.
13. Ren B, Szalai AJ, Hollingshead SK, Briles DE (2004) Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect Immun 72: 114-122.
14. Shaper M, Hollingshead SK, Benjamin WH, Jr., Briles DE (2004) PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected]. Infect Immun 72: 5031-5040.
15. Ferreira DM, Darrieux M, Oliveira ML, Leite LC, Miyaji EN (2008) Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production. Clin Vaccine Immunol 15: 499-505.
16. Ferreira DM, Miyaji EN, Oliveira ML, Darrieux M, Areas AP, et al. (2006) DNA vaccines expressing pneumococcal surface protein A (PspA) elicit protection levels comparable to recombinant protein. J Med Microbiol 55: 375-378.
17. Miyaji EN, Dias WO, Tanizaki MM, Leite LC (2003) Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses. FEMS Immunol Med Microbiol 37: 53-57.
18. Li Y, Wang S, Scarpellini G, Gunn B, Xin W, et al. (2009) Evaluation of new generation Salmonella enterica serovar Typhimurium vaccines with regulated delayed attenuation to induce immune responses against PspA. Proc Natl Acad Sci U S A 106: 593-598.
19. Xin W, Li Y, Mo H, Roland KL, Curtiss R, 3rd (2009) PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae. Infect Immun 77: 4518-4528.
20. Campos IB, Darrieux M, Ferreira DM, Miyaji EN, Silva DA, et al. (2008) Nasal immunization of mice with Lactobacillus casei expressing the Pneumococcal Surface Protein A: induction of antibodies, complement deposition and partial protection against Streptococcus pneumoniae challenge. Microbes Infect 10: 481-488.
21. Hanniffy SB, Carter AT, Hitchin E, Wells JM (2007) Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection. J Infect Dis 195: 185-193.
22. Ferreira DM, Darrieux M, Silva DA, Leite LC, Ferreira JM, Jr., et al. (2009) Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice. Clin Vaccine Immunol 16: 636-645.
23. Oma K, Zhao J, Ezoe H, Akeda Y, Koyama S, et al. (2009) Intranasal immunization with a mixture of PspA and a Toll-like receptor agonist induces specific antibodies and enhances bacterial clearance in the airways of mice. Vaccine 27: 3181-3188.
24. Arulanandam BP, Lynch JM, Briles DE, Hollingshead S, Metzger DW (2001) Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun 69: 6718-6724.
25. Zhang Z, Clarke TB, Weiser JN (2009) Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest 119: 1899-1909.
26. Lu YJ, Gross J, Bogaert D, Finn A, Bagrade L, et al. (2008) Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog 4: e1000159.
27. Basset A, Thompson CM, Hollingshead SK, Briles DE, Ades EW, et al. (2007) Antibody-independent, CD4+ T-cell-dependent protection against pneumococ-cal colonization elicited by intranasal immunization with purified pneumococcal proteins. Infect Immun 75: 5460-5464.
28. Lu YJ, Forte S, Thompson CM, Anderson PW, Malley R (2009) Protection against Pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide. Infect Immun 77: 2076-2083.
29. Lu YJ, Skovsted IC, Thompson CM, Anderson PW, Malley R (2009) Mechanisms in the serotype-independent pneumococcal immunity induced in mice by intranasal vaccination with the cell wall polysaccharide. Microb Pathog 47: 177-182.
30. Malley R, Srivastava A, Lipsitch M, Thompson CM, Watkins C, et al. (2006) Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide. Infect Immun 74: 2187-2195.
31. Reed SG, Bertholet S, Coler RN, Friede M (2009) New horizons in adjuvants for vaccine development. Trends Immunol 30: 23-32.
32. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH (2006) TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol 177: 7980-7989.
33. Berstad AK, Oftung F, Korsvold GE, Haugen IL, Froholm LO, et al. (2000) Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine. Vaccine 18: 2323-2330.
34. McGuirk P, Mills KH (2000) A regulatory role for interleukin 4 in differential inflammatory responses in the lung following infection of mice primed with Th1-or Th2-inducing pertussis vaccines. Infect Immun 68: 1383-1390.
35. Mahon BP, Ryan MS, Griffin F, Mills KH (1996) Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells. Infect Immun 64: 5295-5301.
36. Yano A, Komatsu T, Ishibashi M, Udaka K (2007) Potent CTL induction by a whole cell pertussis vaccine in anti-tumor peptide immunotherapy. Microbiol Immunol 51: 685-699.
37. Berstad AK, Andersen SR, Dalseg R, Dromtorp S, Holst J, et al. (2000) Inactivated meningococci and pertussis bacteria are immunogenic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine. Vaccine 18: 1910-1919.
38. Locht C (2008) A common vaccination strategy to solve unsolved problems of tuberculosis and pertussis? Microbes Infect 10: 1051-1056.
39. Bamberger ES, Srugo I (2008) What is new in pertussis? Eur J Pediatr 167: 133-139.
40. Hale C, Humphreys IR, Hussell T, Bowe F, Clare S, et al. (2004) Mucosal immunisation of murine neonates using whole cell and acellular Pertussis vaccines. Vaccine 22: 3595-3602.
41. Mielcarek N, Debrie AS, Raze D, Bertout J, Rouanet C, et al. (2006) Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog 2: e65.
42. PAHO (2007) Immunization newsletter. Washington D.C. pp 1-8.
43. Hollingshead SK, Becker R, Briles DE (2000) Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun 68: 5889-5900.
44. Darrieux M, Moreno AT, Ferreira DM, Pimenta FC, de Andrade AL, et al. (2008) Recognition of pneumococcal isolates by antisera raised against PspA fragments from different clades. J Med Microbiol 57: 273-278.
45. Moreno AT, Oliveira ML, Ferreira DM, Ho PL, Darrieux M, et al. (2010) Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection. Clin Vaccine Immunol.
46. Zorzeto TQ, Higashi HG, da Silva MT, Carniel Ede F, Dias WO, et al. (2009) Immunogenicity of a whole-cell pertussis vaccine with low lipopolysaccharide content in infants. Clin Vaccine Immunol 16: 544-550.
47. Ferreira DM, Moreno AT, Cianciarullo AM, Ho PL, Oliveira ML, et al. (2009) Comparison of the pulmonary response against lethal and non-lethal intranasal challenges with two different pneumococcal strains. Microb Pathog 47: 157-163.
48. Briles DE, Ades E, Paton JC, Sampson JS, Carlone GM, et al. (2000) Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun 68: 796-800.
49. Dagan R (2009) Serotype replacement in perspective. Vaccine 27 Suppl 3: C22-24.
50. Hollingshead SK, Baril L, Ferro S, King J, Coan P, et al. (2006) Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries. J Med Microbiol 55: 215-221.
51. Pimenta FC, Ribeiro-Dias F, Brandileone MC, Miyaji EN, Leite LC, et al. (2006) Genetic diversity of PspA types among nasopharyngeal isolates collected during an ongoing surveillance study of children in Brazil. J Clin Microbiol 44: 2838-2843.
52. Darrieux M, Miyaji EN, Ferreira DM, Lopes LM, Lopes AP, et al. (2007) Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition. Infect Immun 75: 5930-5938.
53. Tamizifar H, Jennings R, Ali SA, Potter CW (1997) Induction of IL-2 and IFN-gamma in BALB/c mice immunised with subunit influenza A vaccine in combination with whole cell or acellular DTP vaccine. J Med Microbiol 46: 61-66.
54. Tamizifar H, Robinson A, Jennings R, Potter CW (1995) Immune response and protection against influenza A infection in mice immunised with subunit influenza A vaccine in combination with whole cell or acellular DTP vaccine. Vaccine 13: 1539-1546.
55. Prikazsky V, Bock HL (2001) Higher anti-hepatitis B response with combined DTPw-HBV vaccine compared with separate administration in healthy infants at 3, 4 and 5 months of age in Slovakia. Int J Clin Pract 55: 156-161.
56. Nicol M, Huebner R, Mothupi R, Kayhty H, Mbelle N, et al. (2002) Haemophilus influenzae type b conjugate vaccine diluted tenfold in diphtheria-tetanus-whole cell pertussis vaccine: a randomized trial. Pediatr Infect Dis J 21: 138-141.
57. Reinert P, Guy M, Girier B, Szelechowski B, Baudoin B, et al. (2003) [The safety and immunogenicity of an heptavalent pneumococcal polysaccharide conjugate vaccine (Prevenar) administered in association with a whole-cell pertussis-based pediatric combination vaccine (DTP-IPV/PRP-T) to French infants with a two-, three-, and four-month schedule]. Arch Pediatr 10: 1048-1055.
58. Dagan R, Goldblatt D, Maleckar JR, Yaich M, Eskola J (2004) Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. Infect Immun 72: 5383-5391.
59. Fujimoto C, Yu CR, Shi G, Vistica BP, Wawrousek EF, et al. (2006) Pertussis toxin is superior to TLR ligands in enhancing pathogenic autoimmunity, targeted at a neo-self antigen, by triggering robust expansion of Th1 cells and their cytokine production. J Immunol 177: 6896-6903.
60. Orr B, Douce G, Baillie S, Parton R, Coote J (2007) Adjuvant effects of adenylate cyclase toxin of Bordetella pertussis after intranasal immunisation of mice. Vaccine 25: 64-71.
61. Tonon S, Badran B, Benghiat FS, Goriely S, Flamand V, et al. (2006) Pertussis toxin activates adult and neonatal naive human CD4+ T lymphocytes. Eur J Immunol 36: 1794-1804.
62. Banus S, Stenger RM, Gremmer ER, Dormans JA, Mooi FR, et al. (2008) The role of Toll-like receptor-4 in pertussis vaccine-induced immunity. BMC Immunol 9: 21.
63. Fedele G, Celestino I, Spensieri F, Frasca L, Nasso M, et al. (2007) Lipooligosaccharide from Bordetella pertussis induces mature human mono-cyte-derived dendritic cells and drives a Th2 biased response. Microbes Infect 9: 855-863.
64. Quintilio W, Kubrusly FS, Iourtov D, Miyaki C, Sakauchi MA, et al. (2009) Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice. Vaccine 27: 4219-4224.
65. Errea A, Moreno G, Sisti F, Fernandez J, Rumbo M, et al. (2010) Mucosal innate response stimulation induced by lipopolysaccharide protects against Bordetella pertussis colonization. Med Microbiol Immunol.
66. Kim JO, Weiser JN (1998) Association of intrastrain phase variation in quantity of capsular polysaccharide and teichoic acid with the virulence of Streptococcus pneumoniae. J Infect Dis 177: 368-377.
67. Aida Y, Pabst MJ (1990) Removal of endotoxin from protein solutions by phase separation using Triton X-114. J Immunol Methods 132: 191-195.
68. Oliveira ML, Areas AP, Campos IB, Monedero V, Perez-Martinez G, et al. (2006) Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A. Microbes Infect 8: 1016-1024.
69. Ren B, Szalai AJ, Thomas O, Hollingshead SK, Briles DE (2003) Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae. Infect Immun 71: 75-85.